Phio Pharmaceuticals Corp (PHIO)

[Inoviorulez]

Reason why RXI-109 Phase 2a will be positive:

I would be inclined to agree with you except you have to take bits of evidence and piece them together to infer what might come out of the results. There are certain information that you and other investors should have taken note. For starters:

1. RXII used a much lower dose than Pfizer's Excaliard in phase 1 yet achieved greater knockdown. Now if you look at Excaliards trials for Scarring you will notice that it had positive phase 2a results in hypertrophic scars and keloids. Therefore we can infer that RXII's drug should do substantially better than Pfizer's Excaliard drug from the previous statement above. It's just putting two and two together.

2. Did you take note what the CEO said during the Jefferies conference presentation? First he said that the results look amazing and heading in the right direction they wanted. But he noted that the results are still double blind. Although can we really infer that a placebo compound (saline) was able to reduce scars dramatically? I think not, I think RXI-109 showed great reduction of scars and placebo probably nothing otherwise Saline in the market would be a goldmine for scars.

3. CEO has been buying every chance he got and has stopped the last 2 months because he can't buy when a big catalyst event is coming within a 2-month period. Now if the CEO was selling a lot of shares prior to the 2 month period then I would be worried but he did not.

4. Closing bell video on NASDAQ the CEO and I hope you listened closely said " that the doctors giving RXI-109 to patients wanted to use it for themselves jokingly. That doesn't sound to me like bad results does it?

5. Finally you have to look at other clinical trials. The monkey trial in itself is amazing because you can see the true power of the sd-rxRNA platform and RXI-109 itself. The company was only attempting to reduce the mRNA of the retina. That was their only goal but the compound was so strong that it spilled over to the front to knock down the mRNA of cornea